Program Director Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, explains that Avastin (bevacizumab) remains her standard of care for aggressive metastatic breast cancer that requires the use of two agents for optimal control.

She explains that the using two chemotherapy agents may not be sustainable for longer periods of time; whereas paclitaxel in combination with Avastin offers better options for doublet therapy. She believe that Avastin also fulfills is biggest unmet medical need in triple negative breast cancer which is often refractory to chemotherapy.

свернуть